drugset / Trial / NCT06258213

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers

NCT06258213

Phase 1 Completed 90 enrolled Atom Therapeutics Co., Ltd
RandomizedSequentialTriple-blindOther

Summary

A randomized, double-blind, placebo-controlled, dose-escalation study will be conducted in healthy volunteers. This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ABP-745 following single (Part 1) and multiple (Part 2) oral doses.

Timeline

Start
2024-01-23
Primary completion
2024-07-29
Completion
2024-07-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator ABP-745 Unknown 0.5 mg Oral
Comparator ABP-745 Unknown 5 mg Oral
Comparator ABP-745 Unknown 25 mg Oral

Indications